Author Archives: Bruno Quinney

Therapeutic antibodies
#Absci #AI #AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Biologics #Generative AI #Machine learning

How the next generation of AI is reshaping antibody drug discovery

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called ‘Machine learning: developing next generation antibody therapeutics’. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and… Read More

#Featured Podcasts #Podcasts

#Biotech #bit bio #Drug discovery #Human disease models

Bit.bio to develop human cell models for drug discovery 

Biotech company bit.bio has closed a $50 million Series C funding round to scale human cell models for drug discovery.  The company aims to use the funding to accelerate the development of, and access to, its products, scale its operations globally, expand into the multi-billion toxicology market, bolster its… Read More

#Business & Investment #News

Screening patient for AMD
#AMD #Complement Therapeutics #FDA #Geographic atrophy

FDA fast tracks geographic atrophy treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation for a treatment for  geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  CTx001, developed by biotechnology company Complement Therapeutics, is a novel adeno-associated virus (AAV)-based gene therapy designed… Read More

#News #Regulatory

Human cells
#Junevity #Mitochondria #University of California San Francisco

Cellular ageing could be reversed, research reveals 

Cellular ageing could be reprogrammed back towards health, new research finds.  A study published in Proceedings of the National Academy of Sciences (PNAS) shows precise modulation of individual transcription factors can reverse core hallmarks of cellular ageing and restore tissue function in vivo.  The analysis was led by biotechnology company Junevity,… Read More

#News

#Cancer research #RNA #Storm Therapeutics

Biotech companies to develop epitranscriptomic cancer therapies 

Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications.  STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition.   Post-transcriptional modification of RNA, including N6-methyladenosine… Read More

#Business & Investment #Cancer Research #News

Pancreatic cancer
#Clinical trial #Pancreatic cancer

HUTCHMED begins Phase III trial of PDAC treatment 

Biopharmaceutical company HUTCHMED has launched the Phase III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).  PDAC is a highly aggressive form of cancer, representing over 90% of pancreatic cancer cases. Globally, an estimated 511,000 people were diagnosed… Read More

#Cancer Research #News

Patient with dry eye disease using eye drops
#Eye #Genetics #Ocular diseases

New research uncovers genetic causes of sight loss 

Scientists have uncovered new genetic causes of sight loss, paving the way for a genetic diagnosis for thousands of people.  Researchers, analysing data from Genomics England’s National Genomic Research Library (NGRL), found five new genetic causes of retinitis pigmentosa (RP), an eye condition that causes gradual blindness. Read More

#News

Laboratory research
#Antag Therapeutics #Clinical trial #Obesity

Novel obesity drug could be ‘combination partner of choice’ 

Biotechnology company Antag Therapeutics has revealed promising results from its novel GIPR antagonist for the treatment of obesity.  AT7687, a first-in-class GIPR antagonist, was trialled in a Phase I randomised, double-blind, placebo-controlled study. Results show AT7687 demonstrated a favourable safety and tolerability profile across all doses.  The… Read More

#News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

Cancer cells
#EpiBiologics #Financing #Non-small cell lung cancer (NSCLC) #Oncology

Biotech startup raises $107m to advance oncology candidates 

Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies.  The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and… Read More

#Business & Investment #News

#FDA #Investigational New Drug (IND) #Leukaemia #Lymphoma

FDA grants IND clearance to novel BTK degrader 

A novel treatment for relapsed/refractory B-cell malignancies has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA).  APG-3288, developed by biopharmaceutical company Ascentage Pharma, is a novel next-generation BTK-targeted protein degrader. The candidate is designed to induce rapid, potent, highly selective, and sustained degradation of… Read More

#News #Regulatory

#Circio Holding #Infectious diseases #University of Texas

Circio to collaborate with UTMB to treat infectious diseases 

Biotechnology company Circio Holding is set to collaborate with The University of Texas Medical Branch (UTMB) to evaluate treatments for infectious diseases.  The partnership aims to design and test Circio’s circVEC technology for the prevention and treatment of infections, cancer and gene therapy. The technology allows for the long-term expression of proteins, protecting against… Read More

#Business & Investment #News

#ALS #Fast Track designation #FDA

FDA grants Fast Track Designation to ALS treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS).  VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases.  Fast Track is a process designed… Read More

#News #Regulatory

#Eli Lilly #Metabolic diseases #Nimbus #Obesity

Nimbus partners with Lilly on novel obesity treatment 

Drug discovery company Nimbus Therapeutics has partnered with Eli Lilly to develop a novel oral treatment for obesity and other metabolic diseases.  The companies aim to apply Nimbus’ computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery programme addressing a significant unmet need… Read More

#Business & Investment #News

#Biotech #Financing #Metabolic diseases #Obesity

Alveus raises $160m to progress weight loss candidate  

Biotechnology company Alveus Therapeutics has raised $159.8 million to advance its next-generation therapies for obesity and metabolic diseases.  Proceeds from the Series A financing will support Phase II clinical development of ALV-100, the company’s lead programme, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly… Read More

#Business & Investment #News

Monoclonal antibody
#Acute inflammatory conditions #Autoimmune disease #Clinical trial #Monoclonal antibodies

Nucleome to develop first-in-class monoclonal antibody 

Biotechnology company Nucleome Therapeutics is set to advance a potential first-in-class treatment for major chronic inflammatory diseases.  NTP464 is a potential first-in-class monoclonal antibody agonist with strong potency, selectivity and developability characteristics. Nucleome has nominated NTP646 for development.  The target of NTP464 is a novel inflammation checkpoint identified using Nucleome’s proprietary suite of… Read More

#News